Dapagliflozin for chest pain with non-blocked arteries
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests a medicine called dapagliflozin to see if it can reduce chest pain in people whose heart arteries are not blocked but still have reduced blood flow to the heart muscle. It may help improve symptoms and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chest pain, pressure, or shortness of breath with activity.
- You have had a heart test in the past 5 years showing reduced blood flow to the heart muscle, but no major blockages in your arteries.
- You are already on stable heart medication for at least 30 days and do not plan to change it during the trial.
- You do not have diabetes, heart failure with preserved pumping function, or a history of heart bypass surgery.
- You are not currently taking an SGLT2 inhibitor (a type of diabetes medicine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps doctors understand why some people have chest pain even though their main heart arteries are not blocked. Researchers will use special tests to figure out the best treatment for each person's specific type of heart pain.
This early-phase study tests whether dapagliflozin can improve tiny blood-vessel function in women who have heart-ache-like symptoms but no major blockage on heart scans. If it works, it may help symptoms related to “microvascular” heart circulation problems.
This study tests whether a medication called dapagliflozin (a pill for heart failure) can help people with a Fontan circulation who feel short of breath. It aims to improve symptoms and quality of life.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
This trial tests whether a diabetes medication called dapagliflozin can help improve how well the right side of your heart works after off-pump coronary artery bypass grafting surgery (a way to reroute blood around blocked heart arteries). The goal is to see if this drug reduces strain on your heart during recovery.
This trial looks at whether dapagliflozin (a diabetes medicine that helps the kidneys and heart) can lower the chance of atrial fibrillation, an irregular heart rhythm, after coronary artery bypass (CABG) surgery. If you’re scheduled for planned bypass surgery, this study may help reduce post-operative rhythm problems.
Hear when a new Angina With Non-Obstructive Coronary Artery Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.